BioStock: PHI aims for US listing

July 11, 2024
Language flag

Swedish Medtech Phase Holographic Imaging is making significant strides in the United States, establishing itself at the forefront of the rapidly growing regenerative medicine field. PHI is now taking an important step by applying for listing its shares in the US OTCQB market to enhance its presence and opportunities in the US. BioStock talked to CEO Patrik Eschricht to learn more about what this means for the company.

Read the full interview with Patrik Eschricht on biostock.se.

We are very happy about the possibility of dual-listing on the OTCQB, which would be another significant step in PHI’s growth journey as a global company. This dual listing would make it more accessible for international investors to invest in PHI, positively increasing liquidity, boosting shareholder value, and supporting our ongoing growth.

Further reading

Patrik Eschricht and Peter Egelberg shaking hands

BioStock: PHI comments on the new senior positions in the company

BioStock reached out to Patrik Eschricht and Peter Egelberg to better understand the background behind the recent management shift.
PHI CSO Kersti Alm at Biostock

BioStock: PHI on the alliance for cell-based biomanufacturing

Kersti Alm, CSO at PHI, visited BioStock’s studio to talk about the recently created alliance for advancing cell-based biomanufacturing and PHI’s pivotal role in the collaboration.
PHI part of new regenerative medicine alliance

BioStock: PHI part of new regenerative medicine alliance

BioStock contacted Product Manager Lisa Lindström to learn more about PHI’s newly formed technology development alliance for regenerative medicine and what excites her about the future.
Biostock-regenerative-medicine-phi

BioStock: PHI expands market potential with regenerative medicine opportunity

BioStock contacted CFO Patrik Eschricht to find out more about PHI’s visions regarding regenerative medicine, cell-based therapies and automatization of biomanufacturing.
1…45678

Latest News

PHI-accelerates-growth-with-record-order-biostock

BioStock: PHI accelerates growth with record order

PHI recently received its most significant order from Altium, comprising 20 HoloMonitor systems and additional components. This milestone aligns with the positive growth trajectory since the start of the year. PHI is also approaching the final exercise day of their TO 4 warrants on October 3, raising up to SEK 6.2 million before issue costs. BioStock reached out to CEO Patrik Eschricht for a comment.

Notice of Annual General Meeting in Phase Holographic Imaging PHI AB (publ)

The shareholders of Phase Holographic Imaging PHI AB (publ), reg. nr. 556542-7811, are hereby invited to attend the annual general meeting on the 31 October 2024 at 11.00 at the company´s office at Skiffervägen 48 in Lund.

The last day of trading in warrants of series TO 4 is on 1 October 2024

The 1st of October 2024 is the last day of trading in warrants of series TO 4, which were issued in connection with Phase Holographic Imaging PHI AB’s preferential rights issue of units that was carried out in 2022. The exercise period runs until 3 October 2024.
See All News